A computational model for anti-cancer drug sensitivity prediction

Various methods have been developed to build models for predicting drug response in cancer treatment based on patient data through machine learning algorithms. Drug prediction models can offer better patient data classification, optimising sensitivity identification in cancer therapy for suitable drugs. In this paper, a computational model based on Deep Neural Networks has been designed for prediction of anti-cancer drug response based on genetic expression data using publicly available drug profiling datasets from Cancer Cell Line Encyclopedia (CCLE). The model consists of several parts, including continuous drug response prediction, discretization and a drug sensitivity result output. Regularization and compression of neuron connections is also implemented to make the model compact and efficient, outperforming other widely used algorithms, such as elastic net (EN), random forest (RF), support vector regression (SVR) and simple artificial neural network (ANN) in sensitivity analysis and predictive accuracy

생물학적 사전 지식을 활용한 고차원의 다중 오믹스 관계를 찾는 컴퓨터 공학적 접근 방법

학위논문(박사) -- 서울대학교대학원 : 공과대학 컴퓨터공학부, 2021.8. 김선.세포가 어떻게 기능하고 외부 자극에 반응하는지 이해하는 것은 생물학, 의학에서 가장 중요한 관심사 중 하나이다. 기술의 발전으로 과학자들은 단일 생물학적 실험으로 세포의 변화요인들을 쉽게 측정할 수 있게 되었다. 주목할만한 예시로 게놈 시퀀싱, 유전자 발현량 측정, 유전자 발현을 조절하는 후성 유전체 측정 같은 다중 오믹스 데이터가 있다. 세포의 상태를 더 자세히 이해하기 위해서 다중 오믹스 조절자와 유전자 사이의 조절 관계를 알아내는 것이 중요하다. 하지만 다중 오믹스 조절 관계는 매우 복잡하고 모든 세포 상태 특이적인 관계를 실험적으로 검증하는 것은 불가능하다. 따라서, 서로 다른 유형의 고차원 오믹스 데이터로부터 관계를 예측하기 위한 효율적인 컴퓨터 공학적 접근방법이 요구된다. 이러한 고차원 데이터를 처리하는 한 가지 방법은 다양한 데이터베이스에서 선별된 유전자의 기능과 오믹스 간의 관계와 같은 외부 생물학적 지식을 통합하여 활용하는 것이다. 본 박사학위 논문은 생물학적 사전 지식을 활용하여 다중 오믹스 데이터로부터 유전자의 발현을 조절하는 관계를 예측하기 위한 세 가지 컴퓨터 공학적인 접근법을 제안하였다. 첫 번째는 마이크로 알엔에이와 유전자의 일대다 관계를 예측하기 위한 기법이다. 마이크로 알엔에이 표적 예측 문제는 가능한 표적 유전자의 개수가 너무 많으며 거짓 양성과 거짓음성의 비율을 조절해야 하는 문제가 있다. 이러한 문제를 해결하기 위해 마이크로 알엔에이-유전자와 데이터의 맥락 사이의 연관성을 문헌 지식을 활용하여 결정하고 마이크로 알엔에이-유전자 관계를 예측하기 위한 ContextMMIA를 개발하였다. ContextMMIA는 통계적 유의성과 문헌 관련성을 기반으로 마이크로 알엔에이-유전자 관계의 점수를 계산하여 관계의 우선순위를 결정한다. 예후가 다른 유방암 데이터에 대한 실험에서 ContextMMIA는 예후가 나쁜 유방암에서 활성화된 마이크로 알엔에이-유전자 관계를 예측하였고 기존 실험적으로 검증된 관계가 높은 우선순위로 예측되었으며 해당 유전자들이 유방암 관련 경로에 관여하는 것으로 알려졌다. 두 번째는 약물 반응을 일으키는 유전자의 다대일 조절 관계를 예측하기 위한 기법이다. 약물 반응 예측을 위해서 약물 반응 매개 유전자를 결정해야 하며 이를 위해 20,000개 유전자의 다중 오믹스 데이터를 통합 분석하는 방법이 필요하다. 이 문제를 해결하기 위해 저차원 임베딩 방법, 약물-유전자 연관성에 대한 문헌 지식 및 유전자-유전자 상호 작용 지식을 활용하여 약물 반응을 예측하기 위한 DRIM을 개발하였다. DRIM은 오토인코더, 텐서 분해, 약물-유전자 연관성을 이용하여 다중 오믹스 데이터에서 다대일 관계를 결정한다. 결정된 매개 유전자의 조절 관계를 유전자-유전자 상호 작용 지식과 약물 반응 시계열 유전자 발현 데이터의 상호 상관관계를 이용하여 결정한다. 유방암 세포주 데이터에 대한 실험에서 DRIM은 라파티닙이 표적으로 하는 PI3K-Akt 패스웨이에 관여하는 유전자들의 약물 반응 조절 관계를 예측하였고 라파티닙 반응성과 관련된 매개 유전자를 예측하였다. 그리고 예측된 조절 관계가 세포주 특이적인 패턴을 보이는 것을 확인하였다. 세 번째는 세포의 상태를 설명하는 조절자와 유전자의 다대다 조절 관계를 예측하기 위한 기법이다. 다대다 관계 예측을 위해 관찰된 유전자 발현 값과 유전자 조절 네트워크로부터 추정된 유전자 발현 값 사이의 차이를 측정하는 목적 함수를 만들었다. 목적 함수를 최소화하기 위하여 조절인자와 유전자의 수에 따라 기하급수적으로 증가하는 검색 공간을 탐색해야 한다. 이 문제를 해결하기 위해 조절자-유전자 상호 작용 지식을 활용하여 두 가지 연산을 반복하여 조절 관계를 찾는 최적화 기법을 개발하였다. 첫 번째 단계는 네트워크에 간선을 추가하기 위해 강화 학습 기반 휴리스틱을 통해 조절자를 선택하는 다대일 유전자 중심 관계를 탐색하는 단계이다. 두 번째 단계는 네트워크에서 간선을 제거하기 위해 유전자를 확률적으로 선택하는 일대다 조절자 중심 관계를 탐색하는 단계이다. 유방암 세포주 데이터에 대한 실험에서 제안된 방법은 이전의 최적화 방법보다 더 정확한 유전자 발현량 추정을 하였고 조절자 및 유전자 발현 데이터로 유방암 아형 특이적 네트워크를 구성하였다. 또한, 유방암 아형 관련 실험 검증된 조절 관계를 예측하였다. 요약하면, 본 박사학위 논문은 다중 오믹스 조절자와 유전자의 사이의 일대다, 다대일, 다대다 관계를 예측하기 위하여 생물학적 지식을 활용한 컴퓨터 공학적 접근법을 제안하였다. 제안된 방법은 증가하고 있는 분자 생물학 데이터를 분석하여 유전자 조절 상호 작용을 이해함으로써 세포 기능에 대한 심층적인 이해를 도와줄 수 있을 것으로 기대된다.Understanding how cells function or respond to external stimuli is one of the most important questions in biology and medicine. Thanks to the advances in instrumental technologies, scientists can routinely measure events within cells in single biological experiments. Notable examples are multi-omics data: sequencing of genomes, quantifications of gene expression, and identification of epigenetic events that regulate expression of genes. In order to better understand cellular mechanisms, it is essential to identify regulatory relationships between multi-omics regulators and genes. However, regulatory relationships are very complex and it is infeasible to validate all condition-specific relationships experimentally. Thus, there is an urgent need for an efficient computational method to extract relationships from different types of high-dimensional omics data. One way to address these high-dimensional data is to incorporate external biological knowledge such as relationships between omics and functions of genes curated in various databases. In my doctoral study, I developed three computational approaches to identify the regulatory relationships from multi-omics data utilizing biological prior knowledge. The first study proposes a method to predict one-to-m relationships between miRNA and genes. The computational challenge of miRNA target prediction is that there are many miRNA target candidates, and the ratio of false positives to false negatives needs to be adjusted. This challenge is addressed by utilizing literature knowledge for determining the association between miRNA-gene and a given context. In this study, I developed ContextMMIA to predict miRNA-gene relationships from miRNA and gene expression data. ContextMMIA computes scores of miRNA-gene relationships based on statistical significance and literature relevance and prioritizes the relationships based on the scores. In experiments on breast cancer data with different prognosis, ContextMMIA predicted differentially activated miRNA-gene relationships in invasive breast cancer. The experimentally verified miRNA-gene relationships were predicted with high priority and those genes are known to be involved in breast cancer-related pathways. The second study proposes a method to predict n-to-one relationships between regulators and gene on drug response. The computational challenge of drug response prediction is how to integrate multi-omics data of 20,000 genes for determining drug response mediator genes. This challenge is addressed by utilizing low-dimensional embedding methods, literature knowledge of drug-gene associations, and gene-gene interaction knowledge. For this problem, I developed DRIM to predict drug response relationships from the multi-omics data and drug-induced time-series gene expression data. DRIM uses autoencoder, tensor decomposition, and drug-gene association to determine n-to-one relationships from multi-omics data. Then, regulatory relationships of mediator genes are determined by gene-gene interaction knowledge and cross-correlation of drug-induced time-series gene expression data. In experiments on breast cancer cell line data, DRIM extracted mediator genes relevant to drug response and regulatory relationships of genes involved in the PI3K-Akt pathway targeted by lapatinib. In addition, DRIM revealed distinguished patterns of relationships in breast cancer cell lines with different lapatinib resistance. The third study proposes a method to predict n-to-m relationships between regulators and genes. In order to predict n-to-m relationships, this study formulated an objective function that measures the deviation between observed gene expression values and estimated gene expression values derived from gene regulatory networks. The computational challenge of minimizing the objective function is to navigate the search space of relationships exponentially increasing according to the number of regulators and genes. This challenge is addressed by the iterative local optimization with regulator-gene interaction knowledge. In this study, I developed a two-step iterative RL-based method to predict n-to-m relationships from regulator and gene expression data. The first step is to explore the n-to-one gene-oriented step that selects regulators by reinforcement learning based heuristic to add edges to the network. The second step is to explore the one-to-m regulator-oriented step that stochastically selects genes to remove edges from the network. In experiments on breast cancer cell line data, the proposed method constructed breast cancer subtype-specific networks from the regulator and gene expression profiles with a more accurate gene expression estimation than previous combinatorial optimization methods. Moreover, regulatory relationships involved in the networks were associated with breast cancer subtypes. In summary, in this thesis, I proposed computational methods for predicting one-to-m, n-to-one, and n-to-m relationships between multi-omics regulators and genes utilizing external domain knowledge. The proposed methods are expected to deepen our knowledge of cellular mechanisms by understanding gene regulatory interactions by analyzing the ever-increasing molecular biology data such as The Cancer Genome Atlas, Cancer Cell Line Encyclopedia.Chapter 1 Introduction 1 1.1 Biological background 1 1.1.1 Multi-omics analysis 1 1.1.2 Multi-omics relationships indicating cell state 2 1.1.3 Biological prior knowledge 4 1.2 Research problems for the multi-omics relationship 6 1.3 Computational challenges and approaches in the exploring multiomics relationship 6 1.4 Outline of the thesis 12 Chapter 2 Literature-based condition-specific miRNA-mRNA target prediction 13 2.1 Computational Problem & Evaluation criterion 14 2.2 Related works 15 2.3 Motivation 17 2.4 Methods 20 2.4.1 Identifying genes and miRNAs based on the user-provided context 22 2.4.2 Omics Score 23 2.4.3 Context Score 24 2.4.4 Confidence Score 26 2.5 Results 26 2.5.1 Pathway analysis 27 2.5.2 Reproducibility of validated targets in humans 31 2.5.3 Sensitivity tests when different keywords are used 33 2.6 Summary 34 Chapter 3 DRIM: A web-based system for investigating drug response at the molecular level by condition-specific multi-omics data integration 36 3.1 Computational Problem & Evaluation criterion 37 3.2 Related works 38 3.3 Motivation 42 3.4 Methods 44 3.4.1 Step 1: Input 45 3.4.2 Step 2: Identifying perturbed sub-pathway with time-series 45 3.4.3 Step 3: Embedding multi-omics for selecting potential mediator genes 47 3.4.4 Step 4: Construct TF-regulatory time-bounded network and identify regulatory path 52 3.4.5 Step 5: Analysis result on the web 52 3.5 Case study: Comparative analysis of breast cancer cell lines that have different sensitivity with lapatinib 54 3.5.1 Multi-omics analysis result before drug treatment 56 3.5.2 Time-series gene expression analysis after drug treatment 57 3.6 Summary 61 Chapter 4 Combinatorial modeling and optimization using iterative RL search for inferring sample-specific regulatory network 63 4.1 Computational Problem & Evaluation criterion 64 4.2 Related works 64 4.3 Motivation 66 4.4 Methods 68 4.4.1 Formulating an objective function 68 4.4.2 Overview of an iterative search method 70 4.4.3 G-step for exploring n-to-one gene-oriented relationship 73 4.4.4 R-step for exploring one-to-m regulator-oriented relationship 79 4.5 Results 80 4.5.1 Cancer cell line data 80 4.5.2 Hyperparameters 81 4.5.3 Quantitative evaluation 82 4.5.4 Qualitative evaluation 83 4.6 Summary 86 Chapter 5 Conclusions 88 국문초록 111박

Machine Learning and Integrative Analysis of Biomedical Big Data.

Recent developments in high-throughput technologies have accelerated the accumulation of massive amounts of omics data from multiple sources: genome, epigenome, transcriptome, proteome, metabolome, etc. Traditionally, data from each source (e.g., genome) is analyzed in isolation using statistical and machine learning (ML) methods. Integrative analysis of multi-omics and clinical data is key to new biomedical discoveries and advancements in precision medicine. However, data integration poses new computational challenges as well as exacerbates the ones associated with single-omics studies. Specialized computational approaches are required to effectively and efficiently perform integrative analysis of biomedical data acquired from diverse modalities. In this review, we discuss state-of-the-art ML-based approaches for tackling five specific computational challenges associated with integrative analysis: curse of dimensionality, data heterogeneity, missing data, class imbalance and scalability issues

Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system

Despite explosive growth in the development of nano-drug delivery systems (NDDS) targeting tumors in the last few decades, clinical translation rates are low owing to the lack of efficient models for evaluating and predicting responses. Microfluidics-based tumor-on-a-chip (TOC) systems provide a promising approach to address these challenges. The integrated engineered platforms can recapitulate complex in vivo tumor features at a microscale level, such as the tumor microenvironment, three-dimensional tissue structure, and dynamic culture conditions, thus improving the correlation between results derived from preclinical and clinical trials in evaluating anticancer nanomedicines. The specific focus of this review is to describe recent advances in TOCs for the evaluation of nanomedicine, categorized into six sections based on the drug delivery process: circulation behavior after infusion, endothelial and matrix barriers, tumor uptake, therapeutic efficacy, safety, and resistance. We also discuss current issues and future directions for an end-use perspective of TOCs

Multi-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives.

Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential therapeutics and regulatory protocols. The technology is expected to boost the development of novel therapies and accelerate the discovery of drug combinations in the coming years. This has led to the development of multi-organ-on-a-chip (MOC) for recapitulating various organs involved in the drug-body interactions. In this review, we discuss the current MOCs used in screening small-molecule drugs and then focus on the dynamic process of drug absorption, distribution, metabolism, and excretion. We also address appropriate materials used for MOCs at low cost and scale-up capacity suitable for high-performance analysis of drugs and commercial high-throughput screening platforms

Correlation between cell line chemosensitivity and protein expression pattern as new approach for the design of targeted anticancer small molecules

BACKGROUND AND RATIONALE: Over the past few decades, several databases with a significant amount of biological data related to cancer cells and anticancer agents (e.g.: National Cancer Institute database, NCI; Cancer Cell Line Encyclopedia, CCLE; Genomic and Drug Sensitivity in Cancer portal, GDSC) have been developed. The huge amount of heterogeneous biological data extractable from these databanks (among all, drug response and protein expression) provides a real foundation for predictive cancer chemogenomics, which aims to investigate the relationships between genomic traits and the response of cancer cells to drug treatment with the aim to identify novel therapeutic molecules and targets. In very recent times many computational and statistical approaches have been proposed to integrate and correlate these heterogeneous biological data sequences (protein expression – drug response), with the aim to assign the putative mechanism of action of anticancer small molecules with unknown biological target/s. The main limitation of all these computational methods is the need for experimental drug response data (after screening data). From this point of view, the possibility to predict in silico the antiproliferative activity of new/untested small molecules against specific cell lines, could enable correlations to be found between the predicted drug response and protein expression of the desired target from the very earliest stages of research. Such an innovative approach could allow to select the compounds with molecular mechanisms that are more likely to be connected with the target of interest preliminary to the in vitro assays, which would be a critical aid in the design of new targeted anticancer agents. RESULTS: In the present study, we aimed to develop a new innovative computational protocol based on the correlation of drug activity and protein expression data to support the discovery of new targeted anticancer agents. Compared with the approaches reported in the literature, the main novelty of the proposed protocol was represented by the use of predicted antiproliferative activity data, instead of experimental ones. To this aim, in the first phase of the research the new in silico Antiproliferative Activity Predictor (AAP) tool able to predict the anticancer activity (expressed as GI50) of new/untested small molecules against the NCI-60 panel was developed. The ligand-based tool, which took the advantages of the consolidated expertise of the research group in the manipulation of molecular descriptors, was adequately validated and the reliability of the prediction was further confirmed by the analysis of an in-house database and subsequent evaluation of a set of molecules selected by the NCI for the one-dose/five-doses antiproliferative assays. In the second part of the study, a new computational method to correlate drug activity data and protein expression pattern data was proposed and evaluated by analysing several case studies of targeted drugs tested by NCI, confirming the reliability of the proposed method for the biological data analysis. In the last part of the project the proposed correlation approach was applied to design new small molecules as selective inhibitors of Cdc25 phosphatase, a well-known protein involved in carcinogenic processes. By means of this innovative approach, integrated with other classical ligand/structures-based techniques, it was possible to screen a large database of molecular structures, and to select the ones with optimal relationship with the focused target. In vitro antiproliferative and enzymatic inhibition assays of the selected compounds led to the identification of new structurally heterogeneous inhibitors of Cdc25 proteins and confirmed the results of the in silico analysis. CONCLUSIONS: Collectively, the obtained results showed that the correlation between protein expression pattern and chemosensitivity is an innovative, alternative, and effective method to identify new modulators for the selected targets. In contrast to traditional in silico methods, the proposed protocol allows for the selection of molecular structures with heterogeneous scaffolds, which are not strictly related to the binding sites and with chemical-physical features that may be more suitable for all the pathways involved in the overall mechanism. The biological assays further corroborate the robustness and the reliability of this new approach and encourage its application in the anticancer targeted drug discovery field